How to buy Acceleron Pharma stock

Acceleron Pharma Inc is a biotechnology business based in the US. Acceleron Pharma shares (XLRN) are listed on the NASDAQ and all prices are listed in US Dollars. Acceleron Pharma employs 312 staff and has a trailing 12-month revenue of around 0.00.

Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Acceleron Pharma stock price (NASDAQ: XLRN)

Use our graph to track the performance of XLRN stocks over time.

Acceleron Pharma shares at a glance

• Key figures

Information last updated 2022-01-16.

52-week range	$113.49 - $189.99
50-day moving average more info button	$169.49
200-day moving average more info button	$137.95
Wall St. target price	$178.88
PE ratio more info button	N/A
Dividend yield more info button	N/A (0%)
Earnings per share (TTM) more info button	$-4.20

Buy Acceleron Pharma shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Acceleron Pharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Acceleron Pharma price performance over time

Historical closes compared with the close of $N/A from 2021-12-08

1 week (2022-06-21)	N/A
1 month (2022-05-29)	N/A
3 months (2022-03-29)	N/A
6 months (2021-12-29)	N/A

1 year (2021-07-02)	-100.00%
2 years (2020-07-02)	-100.00%
3 years (2019-07-02)	-100.00%
5 years (2017-06-30)	-100.00%

Acceleron Pharma financials

Revenue TTM	$112.8 million
Gross profit TTM	$-81,394,000
Return on assets TTM	-18.4%
Return on equity TTM	-31.59%
Profit margin	-226.01%
Book value	$11.75
Market capitalisation more info button	$10.9 billion

TTM: trailing 12 months

Acceleron Pharma share dividends

We're not expecting Acceleron Pharma to pay a dividend over the next 12 months.

Acceleron Pharma share price volatility

Over the last 12 months, Acceleron Pharma's shares have ranged in value from as little as $113.49 up to $189.99. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Acceleron Pharma's is 0.1314. This would suggest that Acceleron Pharma's shares are less volatile than average (for this exchange).

Acceleron Pharma overview

Acceleron Pharma Inc. , a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. It offers REBLOZYL (luspatercept-aamt), a first-in-class erythroid maturation agent, for the treatment of anemia in adult patients with beta-thalassemia and transfusion-dependent anemia. The company is also developing Sotatercept, an activin receptor type IIA fusion protein, for the treatment of patients with pulmonary arterial hypertension; ACE-1334, a pulmonary therapeutic candidate that is in Phase I clinical trials; and luspatercept-aamt for non-transfusion-dependent beta-thalassemia patients and lower-risk myelodysplastic syndrome patients. It has a license agreements with the Salk Institute for Biological Studies for the cloning of type II activin receptors; and license agreement with Fulcrum Therapeutics, Inc. to identify small molecules designed to modulate specific pathways associated with a targeted indication within the pulmonary disease space. The company was formerly known as Phoenix Pharma, Inc.

Frequently asked questions

What percentage of Acceleron Pharma is owned by insiders or institutions?
Currently 11.697% of Acceleron Pharma shares are held by insiders and 88.283% by institutions. How many people work for Acceleron Pharma?
Latest data suggests 312 work at Acceleron Pharma. When does the fiscal year end for Acceleron Pharma?
Acceleron Pharma's fiscal year ends in December. Where is Acceleron Pharma based?
Acceleron Pharma's address is: 128 Sidney Street, Cambridge, MA, United States, 02139 What is Acceleron Pharma's ISIN number?
Acceleron Pharma's international securities identification number is: US00434H1086 What is Acceleron Pharma's CUSIP number?
Acceleron Pharma's Committee on Uniform Securities Identification Procedures number is: 00434H108